---
figid: PMC8010717__nihms-1677737-f0014
figlink: pmc/articles/PMC8010717/figure/F14/
number: F8
caption: The cooperative role of the Wnt/β-catenin and PI3K/Akt pathway in resistance
  to anti-cancer therapies, including immune escape, made the Pten:β-catAct double
  mutant mice served as an ideal model to study cancer therapy resistance. We found
  that cooperative Akt:β-catenin signaling is particularly critical for therapy-resistant
  LSCs. a, Investigating the mechanism underlying this resistance, we unexpectedly
  found that Akt-activated β-catenin binds to multiple IC genes, which are expressed
  on LSCs. b, In identifying DXR as an inhibitor of Akt:β-catenin interaction at low
  doses, we found that DXR could be repurposed as a targeted therapy for resistant
  LSCs, in part by inhibiting multiple ICs, particularly PD-1/PD-L1. Notably, LSCs
  but not blast cells exhibit unique properties of immune resistance, which can be
  reduced with low-dose DXR.
pmcid: PMC8010717
papertitle: Overcoming Wnt-β-catenin dependent anticancer therapy resistance in leukaemia
  stem cells.
reftext: John M. Perry, et al. Nat Cell Biol. ;22(6):689-700.
pmc_ranked_result_index: '28528'
pathway_score: 0.5122547
filename: nihms-1677737-f0014.jpg
figtitle: Overcoming Wnt-Beta-catenin dependent anticancer therapy resistance in leukaemia
  stem cells
year: ''
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8010717__nihms-1677737-f0014.html
  '@type': Dataset
  description: The cooperative role of the Wnt/β-catenin and PI3K/Akt pathway in resistance
    to anti-cancer therapies, including immune escape, made the Pten:β-catAct double
    mutant mice served as an ideal model to study cancer therapy resistance. We found
    that cooperative Akt:β-catenin signaling is particularly critical for therapy-resistant
    LSCs. a, Investigating the mechanism underlying this resistance, we unexpectedly
    found that Akt-activated β-catenin binds to multiple IC genes, which are expressed
    on LSCs. b, In identifying DXR as an inhibitor of Akt:β-catenin interaction at
    low doses, we found that DXR could be repurposed as a targeted therapy for resistant
    LSCs, in part by inhibiting multiple ICs, particularly PD-1/PD-L1. Notably, LSCs
    but not blast cells exhibit unique properties of immune resistance, which can
    be reduced with low-dose DXR.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT2
  - AKT3
  - AKT1
  - CTNNB1
  - CD8A
  - CD8B
  - DXR
genes:
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: B-catenin
  symbol: BCATENIN
  source: bioentities_symbol
  hgnc_symbol: CTNNB1
  entrez: '1499'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: B-catenin
  symbol: BCATENIN
  source: bioentities_symbol
  hgnc_symbol: CTNNB1
  entrez: '1499'
- word: CD8+
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8A
  entrez: '925'
- word: CD8+
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8B
  entrez: '926'
- word: B-catenin
  symbol: BCATENIN
  source: bioentities_symbol
  hgnc_symbol: CTNNB1
  entrez: '1499'
- word: CD8+
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8A
  entrez: '925'
- word: CD8+
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8B
  entrez: '926'
- word: B-catenin
  symbol: BCATENIN
  source: bioentities_symbol
  hgnc_symbol: CTNNB1
  entrez: '1499'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: B-catenin
  symbol: BCATENIN
  source: bioentities_symbol
  hgnc_symbol: CTNNB1
  entrez: '1499'
- word: B-catenin
  symbol: BCATENIN
  source: bioentities_symbol
  hgnc_symbol: CTNNB1
  entrez: '1499'
- word: CD8+
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8A
  entrez: '925'
- word: CD8+
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8B
  entrez: '926'
- word: B-catenin
  symbol: BCATENIN
  source: bioentities_symbol
  hgnc_symbol: CTNNB1
  entrez: '1499'
chemicals:
- word: DXR
  source: MESH
  identifier: D004317
diseases: []
figid_alias: PMC8010717__F8
redirect_from: /figures/PMC8010717__F8
figtype: Figure
---
